“It has been a lot of interest this year in news models of care”, as well in “broader issues in drug user health”, says Jeffrey Lazarus, INHSU 2018 co-convenor. “We are getting beyond just looking at hepatitis C in people who inject drugs, and are including broader issues about improving health and well-being”, adds the specialist in an interview to News Farma.
Try to come-up with a comprehensive framework that helps to understand why certain people, particularly people who inject drugs, have difficulty accessing to DAA therapy was the main goal of the Stine Høj’s presentation. In an interview to News Farma, the specialist from Centre de Recherche of the Centre hospitalier de l'Université de Montréal (CHUM) says that this framework “allows us to find a way to intervein and to evaluate the program so we use to try improve treatment optic”.
During the session “Strategies to Facilitate Linkage to Care for PWID in Low and Middle Income Countries”, Shruti Mehta, professor on Johns Hopkins University, gives prominence to the monitoring process. In her belief, “if we don’t know where we start, we don’t know how to guide our programs and we won’t be able to measure the impact”.
During the 18th September, the “Hepatitis C Community Summit” took place, an event that counted with the presence of about 160 participants, including Rui Tato Marinho e Ricardo Baptista Leite. One of the main conclusions of the meeting was the necessity of “holistic work”. As Erin O’Mara, from the European Network of People Who Use Drugs, says “we all need to be working more in partnerships”.